Compare DNTH & SHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNTH | SHC |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | 92 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.6B |
| IPO Year | 2018 | 2020 |
| Metric | DNTH | SHC |
|---|---|---|
| Price | $82.21 | $15.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 7 |
| Target Price | ★ $121.00 | $20.33 |
| AVG Volume (30 Days) | 909.4K | ★ 2.3M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 68.75 |
| EPS | N/A | ★ 0.09 |
| Revenue | $2,036,000.00 | ★ $1,163,617,000.00 |
| Revenue This Year | N/A | $7.51 |
| Revenue Next Year | $29.48 | $6.00 |
| P/E Ratio | ★ N/A | $172.17 |
| Revenue Growth | N/A | ★ 5.74 |
| 52 Week Low | $16.77 | $10.94 |
| 52 Week High | $96.50 | $19.85 |
| Indicator | DNTH | SHC |
|---|---|---|
| Relative Strength Index (RSI) | 47.09 | 48.79 |
| Support Level | $79.27 | $15.00 |
| Resistance Level | $92.41 | $16.47 |
| Average True Range (ATR) | 5.51 | 0.53 |
| MACD | -0.21 | -0.03 |
| Stochastic Oscillator | 54.28 | 43.98 |
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.